Life Science Nation Newsletter  |  July 28,  2016  |  Issue 172

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (July 21  - July 27)
Seeks Clinical-Stage Therapeutics & Medical Devices
Focuses New Fund on Southeast Life Science Deals
Seeks Therapeutics, Devices & Industrial Biotech Worldwide
Seeks Early-Stage Medtech, Diagnostics and Healthcare IT
In This Issue
News
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Videos
RESI Landing on MaRS

RESI on MaRS Investors Panel

By Caitlin Kramer, Research Analyst, LSN

Each phase of drug development offers its own unique challenges. The generation of lead compounds that may advance through the pipeline of FDA approval is a costly process, and new molecular entities that are advanced as leads through the process of FDA approval face abundant chances of failure: the likelihood of a given compound making it from Phase I through to approval is only 11.8%*. 

Entrepreneurs and researchers developing drugs outside of big pharma will need to understand the costs facing an asset at every stage, and have a plan for how to efficiently structure their capital raises and outreach...

By Cole Bunn, Senior Research Analyst, LSN

Due to their recent trend toward making direct allocations (as opposed to fund investments) family offices have certainly caught the attention of biotech and medtech entrepreneurs, with many early stage companies keen to add one to their cap table.

Viewed as deep-pocketed, patient capital sources, entrepreneurs tend to have a lot of misconceptions surrounding family offices. Family offices are notoriously heterogeneous; they come in many shapes and sizes and no specific investment characteristics apply to them all. At our most recent RESI event at the MaRS Discovery District, representatives from four different family offices spoke to how they like to be approached, what they look for in an entrepreneur and the importance of the relationship, the types of deals they like to do and what they avoid.

Moderated by Dennis Ford, Founder & CEO of Life Science Nation and the RESI Conference Series, this session featured the following:
  • Hugo Peris, Board Member, Salvat Biotech
  • Sunil Selby, Managing Partner, Trellis Capital
  • Ron Paliwoda, Founder & President, Paliwoda Group
  • Sergei Petukhov, Partner, Enso Ventures
By Nono Hu, Director of Marketing, LSN

For those that have been following the summer series thus far, you now have a firm hold on the legal landscape for fundraising as well as the importance of and what constitutes a strong set of marketing materials. In order to organize your outreach and keep track of whom you are sending those materials to, we have found that the proper utilization of cloud infrastructure is the best method to maximize your campaign's efficiency.

Chapter 8 of The Life Science Executive's Fundraising Manifesto, "Leveraging a Cloud Infrastructure to Manage an Outbound Campaign," provides a framework for and describes the key functionality that makes some of today's cloud infrastructure so valuable in any type of outbound campaign. From task management to content delivery and large-scale email campaigns with metrics and tracking, this chapter provides an in-depth look at the value these cloud based products can provide...